IncobotulinumtoxinA (Xeomin) : background, mechanism of action, and manufacturing
IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Aesthetic surgery journal - 33(2013), 1 Suppl vom: 27. März, Seite 18S-22S |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lorenc, Z Paul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Botulinum Toxins, Type A |
|---|
| Anmerkungen: |
Date Completed 26.08.2013 Date Revised 20.10.2016 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/1090820X12474633 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM225998157 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM225998157 | ||
| 003 | DE-627 | ||
| 005 | 20231224070430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1090820X12474633 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0753.xml |
| 035 | |a (DE-627)NLM225998157 | ||
| 035 | |a (NLM)23515195 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lorenc, Z Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IncobotulinumtoxinA (Xeomin) |b background, mechanism of action, and manufacturing |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2013 | ||
| 500 | |a Date Revised 20.10.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Neurotransmitter Agents |2 NLM | |
| 650 | 7 | |a Botulinum Toxins, Type A |2 NLM | |
| 650 | 7 | |a EC 3.4.24.69 |2 NLM | |
| 650 | 7 | |a incobotulinumtoxinA |2 NLM | |
| 650 | 7 | |a EC 3.4.24.69 |2 NLM | |
| 700 | 1 | |a Kenkel, Jeffrey M |e verfasserin |4 aut | |
| 700 | 1 | |a Fagien, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Hirmand, Haideh |e verfasserin |4 aut | |
| 700 | 1 | |a Nestor, Mark S |e verfasserin |4 aut | |
| 700 | 1 | |a Sclafani, Anthony P |e verfasserin |4 aut | |
| 700 | 1 | |a Sykes, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Waldorf, Heidi A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Aesthetic surgery journal |d 1997 |g 33(2013), 1 Suppl vom: 27. März, Seite 18S-22S |w (DE-627)NLM096468130 |x 1527-330X |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2013 |g number:1 Suppl |g day:27 |g month:03 |g pages:18S-22S |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1090820X12474633 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2013 |e 1 Suppl |b 27 |c 03 |h 18S-22S | ||